| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Department of Urology, University of California, Davis, School of Medicine, Sacramento, California 95817
Mutations of p53 are common in hormone-refractory prostate cancer (CaP), suggesting the possibility that these mutations may be involved in the progression of CaP to androgen-independent (AI) growth. However, at present no direct evidence has been presented linking p53 mutations with AI growth of CaP. We established five stably transfected LNCaP cell lines: four containing gain-of-function (GOF) mutant p53 alleles (G245S, R248W, R273H, and R273C) and one containing a non-GOF p53 mutant allele (P151S). The four GOF p53 sublines were able to grow under androgen-depleted conditions, whereas the LNCaP parental line, vector-only line, and the non-GOF line were unable to grow. To investigate the mechanism of the AI growth displayed by the GOF p53 mutants, Western blotting or ELISA were used to examine the expression of the androgen receptor (AR), the AR-regulated prostate-specific antigen (PSA), as well as Akt and Bcl-2 under androgen-depleted conditions. On androgen ablation, the levels of AR decreased in the four GOF p53 sublines compared with the control lines. This decreased AR expression was accompanied by attenuated receptor activity, because a decrease in prostate-specific antigen levels compared with parental LNCaP cells was also observed. Levels of phosphorylated Akt increased in both the GOF p53 sublines and the control lines. Bcl-2 remains unchanged or showed reduced expression in all of the cell lines in the absence of androgen compared to the presence of androgen. These observations suggest that GOF p53 mutants mediate the AI growth of LNCaP cells in an AR-independent fashion, and that both Akt and Bcl-2 are not involved in this process.
This article has been cited by other articles:
![]() |
J. X. Zou, L. Guo, A. S. Revenko, C. G. Tepper, A. T. Gemo, H.-J. Kung, and H.-W. Chen Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer Cancer Res., April 15, 2009; 69(8): 3339 - 3346. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Udayakumar, P. Hachem, M. M. Ahmed, S. Agrawal, and A. Pollack Antisense MDM2 Enhances E2F1-Induced Apoptosis and the Combination Sensitizes Androgen-Dependent and Androgen-Independent Prostate Cancer Cells to Radiation Mol. Cancer Res., November 1, 2008; 6(11): 1742 - 1754. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hu, H.-J. Lee, C. Jiang, J. Zhang, L. Wang, Y. Zhao, Q. Xiang, E.-O. Lee, S.-H. Kim, and J. Lu Penta-1,2,3,4,6-O-galloyl-{beta}-D-glucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo Mol. Cancer Ther., September 1, 2008; 7(9): 2681 - 2691. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-L. Devlin, P. C. Mack, R. A. Burich, P. H. Gumerlock, H.-J. Kung, M. Mudryj, and R. W. deVere White Impairment of the DNA Repair and Growth Arrest Pathways by p53R2 Silencing Enhances DNA Damage-Induced Apoptosis in a p53-Dependent Manner in Prostate Cancer Cells Mol. Cancer Res., May 1, 2008; 6(5): 808 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Vinall, K. Hwa, P. Ghosh, C.-X. Pan, P. N. Lara Jr., and R. W. de Vere White Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis Clin. Cancer Res., October 15, 2007; 13(20): 6204 - 6216. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hu, C. Jiang, T. Schuster, G.-X. Li, P. T. Daniel, and J. Lu Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol. Cancer Ther., July 1, 2006; 5(7): 1873 - 1882. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. You, X.-B. Shi, G. DuRaine, D. Haudenschild, C. G. Tepper, S. Hao Lo, R. Gandour-Edwards, R. W. de Vere White, and A. H. Reddi Interleukin-17 Receptor-Like Gene Is a Novel Antiapoptotic Gene Highly Expressed in Androgen-Independent Prostate Cancer Cancer Res., January 1, 2006; 66(1): 175 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, X.-W. Wang, D. Jelovac, T. Nakanishi, M.-h. Yu, D. Akinmade, O. Goloubeva, D. D. Ross, A. Brodie, and A. W. Hamburger The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells PNAS, July 12, 2005; 102(28): 9890 - 9895. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Colombel, S. Filleur, P. Fournier, C. Merle, J. Guglielmi, A. Courtin, A. Degeorges, C. M. Serre, R. Bouvier, P. Clezardin, et al. Androgens Repress the Expression of the Angiogenesis Inhibitor Thrombospondin-1 in Normal and Neoplastic Prostate Cancer Res., January 1, 2005; 65(1): 300 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Hann and A. Balmain Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants J. Virol., November 1, 2003; 77(21): 11588 - 11595. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |